Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

46 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Inhibitor of Apoptosis Proteins Antagonist Induces T-cell Proliferation after Cross-Presentation by Dendritic Cells.
Hoefsmit EP, van Royen PT, Rao D, Stunnenberg JA, Dimitriadis P, Lieftink C, Morris B, Rozeman EA, Reijers ILM, Lacroix R, Shehwana H, Ligtenberg MA, Beijersbergen RL, Peeper DS, Blank CU. Hoefsmit EP, et al. Among authors: rozeman ea. Cancer Immunol Res. 2023 Apr 3;11(4):450-465. doi: 10.1158/2326-6066.CIR-22-0494. Cancer Immunol Res. 2023. PMID: 36753604
Pharmacogenetic variants associated with outcome in patients with advanced gastric cancer treated with fluoropyrimidine and platinum-based triplet combinations: a pooled analysis of three prospective studies.
Meulendijks D, Rozeman EA, Cats A, Sikorska K, Joerger M, Deenen MJ, Beijnen JH, Schellens JHM. Meulendijks D, et al. Among authors: rozeman ea. Pharmacogenomics J. 2017 Oct;17(5):441-451. doi: 10.1038/tpj.2016.81. Epub 2016 Dec 20. Pharmacogenomics J. 2017. PMID: 27995989
Cancer drug addiction is relayed by an ERK2-dependent phenotype switch.
Kong X, Kuilman T, Shahrabi A, Boshuizen J, Kemper K, Song JY, Niessen HWM, Rozeman EA, Geukes Foppen MH, Blank CU, Peeper DS. Kong X, et al. Among authors: rozeman ea. Nature. 2017 Oct 12;550(7675):270-274. doi: 10.1038/nature24037. Epub 2017 Oct 4. Nature. 2017. PMID: 28976960 Free PMC article.
Cooperative targeting of melanoma heterogeneity with an AXL antibody-drug conjugate and BRAF/MEK inhibitors.
Boshuizen J, Koopman LA, Krijgsman O, Shahrabi A, van den Heuvel EG, Ligtenberg MA, Vredevoogd DW, Kemper K, Kuilman T, Song JY, Pencheva N, Mortensen JT, Foppen MG, Rozeman EA, Blank CU, Janmaat ML, Satijn D, Breij ECW, Peeper DS, Parren PWHI. Boshuizen J, et al. Among authors: rozeman ea. Nat Med. 2018 Feb;24(2):203-212. doi: 10.1038/nm.4472. Epub 2018 Jan 15. Nat Med. 2018. PMID: 29334371
Immune checkpoint inhibition-related colitis: symptoms, endoscopic features, histology and response to management.
Geukes Foppen MH, Rozeman EA, van Wilpe S, Postma C, Snaebjornsson P, van Thienen JV, van Leerdam ME, van den Heuvel M, Blank CU, van Dieren J, Haanen JBAG. Geukes Foppen MH, et al. Among authors: rozeman ea. ESMO Open. 2018 Jan 13;3(1):e000278. doi: 10.1136/esmoopen-2017-000278. eCollection 2018. ESMO Open. 2018. PMID: 29387476 Free PMC article. Review.
Targeting tumor-associated acidity in cancer immunotherapy.
Lacroix R, Rozeman EA, Kreutz M, Renner K, Blank CU. Lacroix R, et al. Among authors: rozeman ea. Cancer Immunol Immunother. 2018 Sep;67(9):1331-1348. doi: 10.1007/s00262-018-2195-z. Epub 2018 Jul 5. Cancer Immunol Immunother. 2018. PMID: 29974196 Free PMC article. Review.
Neoadjuvant versus adjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma.
Blank CU, Rozeman EA, Fanchi LF, Sikorska K, van de Wiel B, Kvistborg P, Krijgsman O, van den Braber M, Philips D, Broeks A, van Thienen JV, Mallo HA, Adriaansz S, Ter Meulen S, Pronk LM, Grijpink-Ongering LG, Bruining A, Gittelman RM, Warren S, van Tinteren H, Peeper DS, Haanen JBAG, van Akkooi ACJ, Schumacher TN. Blank CU, et al. Among authors: rozeman ea. Nat Med. 2018 Nov;24(11):1655-1661. doi: 10.1038/s41591-018-0198-0. Epub 2018 Oct 8. Nat Med. 2018. PMID: 30297911 Clinical Trial.
Autoantibody Development under Treatment with Immune-Checkpoint Inhibitors.
de Moel EC, Rozeman EA, Kapiteijn EH, Verdegaal EME, Grummels A, Bakker JA, Huizinga TWJ, Haanen JB, Toes REM, van der Woude D. de Moel EC, et al. Among authors: rozeman ea. Cancer Immunol Res. 2019 Jan;7(1):6-11. doi: 10.1158/2326-6066.CIR-18-0245. Epub 2018 Nov 13. Cancer Immunol Res. 2019. PMID: 30425107
46 results